Neurotech International (ASX: NTI) has signed a development agreement with RH Farma Dooel Skopje (RH Pharma), a subsidiary of European Cannabis Company (ECC), to produce a pharmaceutical-grade, broad-spectrum cannabinoid drug for paediatric neurodevelopmental disorders.
The collaboration will leverage RH Pharma’s proprietary CO2 extraction technology and Good Manufacturing Practice (GMP) capabilities to create a strain-agnostic drug product that meets pharmaceutical standards. Neurotech’s proprietary cannabinoid formulation has demonstrated significant clinical improvements in conditions including autism, Rett syndrome, and PANDAS/PANS.
Under the agreement, Neurotech will make an initial upfront payment of €25,000, with additional services to be provided as required. The partnership is set for an initial 12-month term. RH Pharma will use a controlled recombination process to develop a drug product that aligns with Neurotech’s compositional standards.
Neurotech CEO Dr Anthony Filippis said the agreement supports the company’s strategy to scale production and meet future demand as it advances the regulatory approval process for NTI164 in Australia.
“As we accelerate our plans for registration of NTI164 in Australia via a provisional registration strategy initially, it will be important for Neurotech to scale production to meet future product demand upon regulatory approvals,” Filippis said. “We are delighted to partner with ECC, a company renowned for its expertise in cannabis product development.”
Rebeka Levy, General Manager of ECC, said the partnership aligns with both companies’ goals of delivering high-quality cannabinoid therapies to the global market.
The agreement strengthens Neurotech’s ability to expand into new markets while maintaining the highest pharmaceutical standards in cannabinoid drug development.
